Advertisement
ANATOMICAL PATHOLOGY| Volume 54, ISSUE 1, P55-62, February 2022

Download started.

Ok

Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing

Published:September 10, 2021DOI:https://doi.org/10.1016/j.pathol.2021.05.100

      Summary

      Glioblastomas are frequent malignant brain tumours with a very poor prognosis and a need for new and efficient therapeutic strategies. With the approval of anti-TRK targeted therapies to treat patients with advanced NTRK-rearranged cancers, independent of the type of cancer, potential new treatment opportunities are available for the 0.5–5% of patients with NTRK-rearranged glioblastomas. Identification of these rare NTRK-rearranged glioblastomas requires efficient diagnostic tools and strategies which are evaluated in this study.
      We compared the results of NTRK1, NTRK2 and NTRK3 fluorescent in situ hybridisation (FISH) assays to those of pan-TRK immunohistochemistry (IHC) using two EPR17341 and A7H6R clones in a set of 196 patients with glioblastomas. Cases with at least 15% of positive nuclei using FISH analyses were further analysed using RNA sequencing.
      Above the 15% threshold, seven positive glioblastomas (3.57%) were identified by FISH assays (4 NTRK1, 3 NTRK2, no NTRK3). NTRK rearrangements were confirmed by RNA sequencing analyses in four cases [1 LMNA-NTRK1, 1 PRKAR2A-NTRK2, 1 SPECC1L-NTRK2 and 1 NACC2-NTRK2 fusions, i.e., 4/196 (2%) of NTRK-rearranged tumours in our series] but no rearrangement was detected in three samples with less than 30% of positive tumour nuclei as determined by NTRK1 FISH. Pan-TRK immunostaining showed major discrepancies when using either the EPR17341 or the A7H6R clones for the following criteria: main intensity, H-Score based scoring and homogeneity/heterogeneity of staining (Kappa values <0.2). This led to defining adequate criteria to identify NTRK-rearranged gliomas exhibiting strong and diffuse immunostaining contrasting to the variable and heterogeneous staining in non-NTRK-rearranged gliomas (p<0.0001).
      As assessing NTRK rearrangements has become crucial for glioma therapy, FISH seems to be a valuable tool to maximise access to TRK testing in patients with glioblastomas. In contrast to other cancers, pan-TRK IHC appears of limited interest in this field because there is no ‘on/off’ IHC positivity criterion to distinguish between NTRK-rearranged and non-NTRK-rearranged gliomas. RNA sequencing analyses are necessary in FISH positive cases with less than 30% positive nuclei, to avoid false positivity when scoring is close to the detection threshold.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Pathology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ostrom Q.T.
        • Patil N.
        • Cioffi G.
        • et al.
        CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017.
        Neuro Oncol. 2020; 22: iv1-96
        • Trusheim J.
        • Dunbar E.
        • Battiste J.
        • et al.
        A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma.
        CNS Oncol. 2017; 6: 29-43
        • Stupp R.
        • Hegi M.E.
        • Mason W.P.
        • et al.
        Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
        Lancet Oncol. 2009; 10: 459-466
        • Chinot O.L.
        • Wick W.
        • Mason W.
        • et al.
        Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
        N Engl J Med. 2014; 370: 709-722
        • Gilbert M.R.
        • Dignam J.J.
        • Armstrong T.S.
        • et al.
        A randomized trial of bevacizumab for newly diagnosed glioblastoma.
        N Engl J Med. 2014; 370: 699-708
        • Louis D.N.
        • Perry A.
        • Reifenberger G.
        • et al.
        The 2016 World Health Organization classification of tumors of the central nervous system: a summary.
        Acta Neuropathol. 2016; 131: 803-820
        • Brat D.J.
        • Aldape K.
        • Colman H.
        • et al.
        cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV.
        Acta Neuropathol. 2018; 136: 805-810
        • Le Rhun E.
        • Preusser M.
        • Roth P.
        • et al.
        Molecular targeted therapy of glioblastoma.
        Cancer Treat Rev. 2019; 80: 101896
        • Drilon A.
        • Laetsch T.W.
        • Kummar S.
        • et al.
        Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children.
        N Engl J Med. 2018; 378: 731-739
        • Laetsch T.W.
        • DuBois S.G.
        • Mascarenhas L.
        • et al.
        Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
        Lancet Oncol. 2018; 19: 705-714
        • Drilon A.
        • Siena S.
        • Ou S.I.
        • et al.
        Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1).
        Cancer Discov. 2017; 7: 400-409
        • No authors listed
        Entrectinib OK'd for cancers with NTRK fusions, NSCLC.
        Cancer Discov. 2019; 9: OF2
      1. No authors listed. Larotrectinib OK'd for Cancers with TRK Fusions.
        Cancer Discov. 2019; 9: 8-9
        • Cocco E.
        • Scaltriti M.
        • Drilon A.
        NTRK fusion-positive cancers and TRK inhibitor therapy.
        Nat Rev Clin Oncol. 2018; 15: 731-747
        • Solomon J.P.
        • Hechtman J.F.
        Detection of NTRK fusions: merits and limitations of current diagnostic platforms.
        Cancer Res. 2019; 79: 3163-3168
        • Penault-Llorca F.
        • Rudzinski E.R.
        • Sepulveda A.R.
        Testing algorithm for identification of patients with TRK fusion cancer.
        J Clin Pathol. 2019; 72: 460-467
        • Mosele F.
        • Remon J.
        • Mateo J.
        • et al.
        Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
        Ann Oncol. 2020; 31: 1491-1505
        • Solomon J.P.
        • Linkov I.
        • Rosado A.
        • et al.
        NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls.
        Mod Pathol. 2020; 33: 38-46
        • Gatalica Z.
        • Xiu J.
        • Swensen J.
        • Vranic S.
        Molecular characterization of cancers with NTRK gene fusions.
        Mod Pathol. 2019; 32: 147-153
        • Hechtman J.F.
        • Benayed R.
        • Hyman D.M.
        • et al.
        Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions.
        Am J Surg Pathol. 2017; 41: 1547-1551
        • Bourhis A.
        • Redoulez G.
        • Quintin-Roué I.
        • Marcorelles P.
        • Uguen A.
        Screening for NTRK-rearranged tumors using immunohistochemistry: comparison of 2 different pan-TRK clones in melanoma samples.
        Appl Immunohistochem Mol Morphol. 2020; 28: 194-196
        • Remoué A.
        • Conan-Charlet V.
        • Bourhis A.
        • et al.
        Non-secretory breast carcinomas lack NTRK rearrangements and TRK protein expression.
        Pathol Int. 2019; 69: 94-96
        • Guibourg B.
        • Cloarec E.
        • Conan-Charlet V.
        • et al.
        EPR17341 and A7H6R pan-TRK immunohistochemistry result in highly different staining patterns in a series of salivary gland tumors.
        Appl Immunohistochem Mol Morphol. 2020; 28: 719-724
        • Ginestet F.
        • Lambros L.
        • Le Flahec G.
        • Marcorelles P.
        • Uguen A.
        Evaluation of a dual ALK/ROS1 fluorescent in situ hybridization test in non-small-cell lung cancer.
        Clin Lung Cancer. 2018; 19: e647-e653
        • Walter A.W.
        • Kandula V.V.R.
        • Shah N.
        Larotrectinib imaging response in low-grade glioma.
        Pediatr Blood Cancer. 2020; 67e28002
        • Ziegler D.S.
        • Wong M.
        • Mayoh C.
        • et al.
        Brief report: potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma.
        Br J Cancer. 2018; 119: 693-696
        • Alvarez-Breckenridge C.
        • Miller J.J.
        • Nayyar N.
        • et al.
        Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor.
        NPJ Precis Oncol. 2017; 1: 5
        • Brastianos P.K.
        • Ippen F.M.
        • Hafeez U.
        • Gan H.K.
        Emerging gene fusion drivers in primary and metastatic central nervous system malignancies: a review of available evidence for systemic targeted therapies.
        Oncologist. 2018; 23: 1063-1075
        • Schram A.M.
        • Taylor B.S.
        • Hetchman J.F.
        • et al.
        Abstract LB-302: potential role of larotrectinib (LOXO-101), a selective pan-TRK inhibitor, in NTRK fusion-positive recurrent glioblastoma.
        Cancer Res. 2017; 77 (LB-302)
        • Torre M.
        • Vasudevaraja V.
        • Serrano J.
        • et al.
        Molecular and clinicopathologic features of gliomas harboring NTRK fusions.
        Acta Neuropathol Commun. 2020; 8: 107
        • Woo H.Y.
        • Na K.
        • Yoo J.
        • et al.
        Glioblastomas harboring gene fusions detected by next-generation sequencing.
        Brain Tumor Pathol. 2020; 37: 136-144
        • Okamura R.
        • Boichard A.
        • Kato S.
        • Sicklick J.K.
        • Bazhenova L.
        • Kurzrock R.
        Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics.
        JCO Precis Oncol. 2018; 2018 (PO.18.00183)
        • Ferguson S.D.
        • Zhou S.
        • Huse J.T.
        • et al.
        Targetable gene fusions associate with the IDH wild-type astrocytic lineage in adult gliomas.
        J Neuropathol Exp Neurol. 2018; 77: 437-442
        • Wu G.
        • Diaz A.K.
        • Paugh B.S.
        • et al.
        The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma.
        Nat Genet. 2014; 46: 444-450
        • Wadhwa S.
        • Nag T.C.
        • Jindal A.
        • et al.
        Expression of the neurotrophin receptors Trk A and Trk B in adult human astrocytoma and glioblastoma.
        J Biosci. 2003; 28: 181-188
        • Wang Y.
        • Hagel C.
        • Hamel W.
        • et al.
        C are commonly expressed in human astrocytes and astrocytic gliomas but not by human oligodendrocytes and oligodendroglioma.
        Acta Neuropathol. 1998; 96: 357-364
        • Nishio S.
        • Morioka T.
        • Hamada Y.
        • Fukui M.
        • Nakagawara A.
        Immunohistochemical expression of tyrosine kinase (Trk) receptor proteins in mature neuronal cell tumors of the central nervous system.
        Clin Neuropathol. 1998; 17: 123-130